

Contents

Neuroblastoma Pre-Infusion (2	2026 R3)	1
Neuroblastoma Post-Infusion ((2126 R3)	3

Neuroblastoma Pre-Infusion (2026 R3) Key Fields

- "CIBMTR Research ID"
 - Update: The text was updated from "CIBMTR Recipient ID" to "CIBMTR Research ID."
 - Rationale: The text was updated to match the current format of the key fields.
- "Event date"
 - Update: The text was updated from "Date of HSCT for which this form is being completed" to "Event date."
 - o Rationale: The text was updated to match the current format of the key fields.
- "HSCT Type", "Product Type", "Specify" & "If this is a report of a second or subsequent transplant, check here and continue with question 218"
 - o Removal: These questions were removed from key fields.
 - <u>Rationale</u>: Removing these fields updates the key fields to match the current format.

Subsequent Infusion

- Q1 ("Is this the report of a second or subsequent infusion for the same disease?")
 - Addition: A section with one question to capture if this form is being completed for a second or subsequent infusion was added to the form.
 - Rationale: This captures if the report is for a second or subsequent infusion within the form, not the key fields, which aligns with current form formatting.

Clinical and Laboratory Characteristics at Diagnosis

- Q1 ("What was the date of diagnosis of Neuroblastoma?")
 - Removal: This question is being removed from F2026.
 - Rationale: Diagnosis date is collected on F2402 (Disease Classification). Removing the question from this form reduces burden and prevents data quality issues.

Laboratory Values at Diagnosis of Neuroblastoma

- Q100 ("Is a copy of the DNA report attached?")
 - o Removal: This question is being removed from F2026.
 - Rationale: To comply with best practices, we are removing the question asking if documentation was attached and replacing it with instructional text stating "CIBMTR strongly encourages attaching the DNA report."

CIBMTR® is a research collaboration between the Medical College of Wisconsin and NMDP. This document is proprietary and confidential. No part of this may be disclosed in any manner without the prior written consent of CIBMTR.



Q115 ("Is a copy of the cytogenetic report attached?")

- o Removal: This question is being removed from F2026.
- Rationale: To comply with best practices, we are removing the question asking if documentation was attached and replacing it with instructional text stating "CIBMTR strongly encourages attaching the cytogenetic report."

Q179 ("Specify the best response to chemotherapy (International Neuroblastoma Response Criteria)") (Q177 on R3)

- Update: The disease status options were updated to match the options in Q561 on 2402 R10. The option "not tested / unknown" was updated to "unknown".
- Rationale: This update was made to keep consistency across forms and prevent data quality issues from discrepant options.

Q182 ("Specify reason")

- Removal: This question is being removed from F2026.
- Rationale: This question was only answered if "not evaluable (NE)" was selected in Q179. Since that option was removed, this question is no longer needed.

Q213 ("Best response to line of therapy") (Q210 on R3)

- Update: The disease status options were updated to match the options in Q561 on 2402 R10 except the option "unknown" was kept.
- Rationale: This update was made to keep consistency across forms and prevent data quality issues from discrepant options.

Q214 ("Specify reason")

- o Removal: This question is being removed from F2026.
- Rationale: This question was only answered if "not evaluable (NE)" was selected in Q213. Since that option was removed, this question is no longer needed.

Disease Status Immediately Prior to the Preparative Regimen

- Q240 ("Serum ferritin") & Q241 (Serum ferritin value) & Q242 ("Date of analysis:")
 - o Removal: These questions are being removed from F2026.
 - <u>Rationale</u>: Serum ferritin value prior to the preparatory regimen is collected on F2400 (Pre-Transplant Essential Data). Removing the questions from this form reduces burden and prevents data quality issues.

Q249 ("Specify the disease status immediately prior to the preparative regimen")

- o Removal: This question is being removed from F2026.
- <u>Rationale</u>: The disease status prior to the preparatory regimen is collected on F2402 (Disease Classification). Removing the question from this form reduces burden and prevents data quality issues.

Q270 ("Specify reason")

- o Removal: This question is being removed from F2026.
- Rationale: This question was only answered if "not evaluable (NE)" was selected in Q249. Since Q249 is being removed, this question is no longer needed.



Q271 ("Specify the date the disease status was determined")

- o Removal: This question is being removed from F2026.
- <u>Rationale</u>: The question asking for the date of the disease assessment for was removed from all diseases on F2402. This question is being removed from F2026 to reduce burden and maintain consistency across forms.
- "First Name", "Last Name", "Phone", "Fax number" & "E-mail address"
 - o Removal: These questions were removed from the form.
 - Rationale: These fields are no longer necessary and removing them complies with data capture best practices.

Neuroblastoma Post-Infusion (2126 R3) Key Fields

- "CIBMTR Research ID"
 - Update: The text was updated from "CIBMTR Recipient ID" to "CIBMTR Research ID."
 - o Rationale: The text was updated to match the current format of the key fields.

"Event date"

- Update: The text was updated from "Date of HSCT for which this form is being completed" to "Event date."
- o Rationale: The text was updated to match the current format of the key fields.
- "HSCT Type", "Product Type" & "Specify"
 - o Removal: These questions were removed from key fields.
 - <u>Rationale</u>: Removing these fields updates the key fields to match the current format.

Disease Assessment at the Time of Best Response to HSCT

- Q1 "Compared to the disease status prior to the preparative regimen, what was the best response to HSCT since the date of the last report? (Include response to any post-HSCT treatment planned as of Day 0.)"
 - Update: The disease status options were updated to match the options in Q561 on 2402 R10. The option "unknown / not tested" was updated to "unknown".
 - Rationale: This update was made to keep consistency across forms and prevent data quality issues from discrepant options.
- Q158 "What is the current disease status?"
 - Update: The disease status options were updated to match the options in Q561 on 2402 R10, but the option "unknown" was added.
 - Rationale: This update was made to keep consistency across forms and prevent data quality issues from discrepant options.
- "First Name", "Last Name", "Phone", "Fax number" & "E-mail address"
 - o Removal: These questions were removed from the form.



o <u>Rationale</u>: These fields are no longer necessary and removing them complies with data capture best practices.



CIBMTR® is a research collaboration between the Medical College of Wisconsin and NMDP. This document is proprietary and confidential. No part of this may be disclosed in any manner without the prior written consent of CIBMTR.

Release Date:12/12/2025 Page **4** of **4**